Tickerover
Healthcare

BAX Stock Analysis

Baxter International Inc. · current price $26.12 (+0.75% today)

Solid setup — 3/4 EPS beats. Momentum, fundamentals and macro indicators are aligned.
★★★★
Quality
📊

The six-pillar scorecard

Momentum
62
Drifting higher
price trend
Growth
25
Barely growing
sales & profit growth
Quality
61
Solid fundamentals
profitability & balance sheet
Valuation
20
Expensive
is the price fair?
Sentiment
32
Out of favour
analyst & crowd mood
Risk
73
Low risk
volatility & drawdown

Each pillar is scored 0-100 inside the stock’s own peer group, so a chipmaker is measured against chipmakers. These are quality descriptors, not buy or sell signals.

📉

The picture

What drove the scoreThe seven components contributing most, each read out of 100.
GrowthGrowth: 7070Trend strengthTrend strength: 100100Relative strengthRelative strength: 6565Earnings qualityEarnings quality: 8484RSI zoneRSI zone: 6060Earnings accelerationEarnings acceleration: 100100FundamentalsFundamentals: 6464
Margin profileWhat survives each step down the income statement.
GrossGross: 34.1%34.1%OperatingOperating: 14.4%14.4%NetNet: -9.3%-9.3%Free cash flowFree cash flow: 7.1%7.1%
EPS surpriseReported EPS against estimate, last four quarters.
2026-06: +52.5% vs estimate+53%2026-062026-03: +15.9% vs estimate+16%2026-032025-12: -17.8% vs estimate-18%2025-122025-09: +15.4% vs estimate+15%2025-09
👁

Hype Check

Reading BAX’s price and volume history…

The audit — what has to hold for this thesis

Checking the areas that decide this thesis…

AI-generated from the company’s own filings and recent coverage, and it can be incomplete or wrong. A PASS is a reading of the cited evidence, not a verified fact and not a reason to buy. Follow each citation to the source.

🛡

Dilution Check

Reading BAX’s filings…

📣

Latest earnings

LAST EARNINGS Baxter International Inc. (BAX)

Latest earnings

EPS
$0.69 vs $0.60 est · +15.4% vs estimate BEAT
Revenue
$2.96B · +4.4% YoY
Stock reaction (1M)
-2.3%
Beat streak
3 of last 4 quarters
💰

Valuation

P/E
12.8×
Forward P/E
12.8×
PEG
36.68
Price / Sales
1.2×
Price / Book
2.2×
EV / EBITDA
11.1×
Analyst target
$28.73
Target range
$23.00 – $40.00
Implied upside
+10.0%
🩺

Financial health

Gross margin
34.1%
Operating margin
14.4%
Net margin
-9.3%
FCF margin
7.1%
Return on equity
-14.4%
Debt / equity
1.56
Revenue growth YoY
+5.3%
EPS growth YoY
+36.8%
📈

Technicals

$15.7352-week range$30.00
50-day MA
$24.19
200-day MA
$20.16
ATR (14)
0.67
Beta
0.59
1-month return
-2.3%
🗓️

Earnings

QuarterEPSEst.SurpriseResult
2025-09-30$0.69$0.60+15.4%Beat
2025-12-31$0.44$0.54-17.8%Miss
2026-03-31$0.36$0.31+15.9%Beat
2026-06-30$0.56$0.37+52.5%Beat
Beat 3 of the last 4 quarters.
🏛️

Ownership & risk

Short % of float
0.07%
Dividend yield
0.15%
Beta
0.59
📰

Latest news on BAX

🔗

Similar stocks in Healthcare

Frequently asked

What is BAX's Quant Score?

Baxter International Inc. (BAX) currently has a TickerMover Quant Score of 64/100, rated ★★★★ Quality. The Quant Score is a quantitative composite across six research pillars — momentum, quality, growth, valuation, sentiment and risk. It is research information, not investment advice.

Is Baxter International Inc. (BAX) a buy?

TickerMover does not give buy or sell recommendations. BAX scores 64/100 (★★★★ Quality) on our quantitative research model — a screening signal, not a personal recommendation. Do your own research, and consider an FCA-authorised adviser before investing.

How often is BAX's score updated?

BAX's Quant Score and underlying data refresh through US market hours (about every five minutes), using public market and fundamental data.

Get the full live dashboard

Real-time scoring, conflict detection, Reverse DCF and peer comparison — free while in beta.

Open the dashboard for BAX →